Form 4: MaxCyte Director Stanley Erck Receives Annual Equity Grant

MaxCyte, Inc. Director Stanley C. Erck reported the acquisition of 29,210 restricted stock units and 50,790 stock options as part of his annual compensation.

Summary

• Stanley C. Erck, a Director of MaxCyte, Inc. (MXCT), acquired 29,210 shares of Common Stock in the form of Restricted Stock Units (RSUs) and 50,790 stock options.
• The transaction occurred on June 18, 2025.
• The RSUs were acquired at a price of $0 and represent a contingent right to receive one share of Common Stock each. These RSUs are scheduled to vest on June 18, 2026, contingent on Mr. Erck's continuous service.
• The stock options have an exercise price of $2.11 per share and expire on June 17, 2035.
• These grants are part of the Issuer's Equity Grant Policy for non-employee directors.
• Following these transactions, Mr. Erck beneficially owns 298,328 shares of Common Stock and 50,790 stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new positive or negative company developments. It's a standard compensation event.

Positives

• The grant of equity to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is a routine annual grant, indicating adherence to established compensation policies for non-employee directors.

Future Outlook

The vesting of the restricted stock units on June 18, 2026, is contingent upon the reporting person's continuous service as a director.

Management Comments

• The annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors.

Industry Context

This type of equity grant is a standard practice in the biotechnology and life sciences industry for compensating non-employee directors, aiming to align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to non-employee directors is a common compensation structure across the biotechnology and pharmaceutical sectors, similar to practices observed at companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT), which frequently use equity awards to incentivize their board members.
• The specific mix and volume of equity awards are typically benchmarked against peer groups to ensure competitive compensation and retention of talent.

Corporate Governance

Related Party Transactions

• The grant of equity (Restricted Stock Units and Stock Options) by MaxCyte, Inc. to its Director, Stanley C. Erck, constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.

Next Steps

• The 29,210 Restricted Stock Units are scheduled to vest on June 18, 2026, subject to continuous service.
• The 50,790 Stock Options can be exercised until their expiration date of June 17, 2035.

Key Dates

Keywords

MaxCyte, MXCT, Stanley C. Erck, SEC Form 4, insider transaction, restricted stock units, RSUs, stock options, director compensation, equity grant, beneficial ownership